Skip to main content

Edgewise Therapeutics, Inc 10-Q for FY2026 Q3

Edgewise Therapeutics, Inc. (EWTX)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

Edgewise Therapeutics, Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Edgewise reported that Servier announced on November 3, 2026 that sevasemten’s pivotal GRAND CANYON study in Becker muscular dystrophy missed its primary and secondary endpoints; milestone payments remain contingent on regulatory and commercial outcomes controlled by Servier. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net income
$1.17B
compared with a net loss of $40.67M a year earlier
Diluted EPS
$9.65
compared with -$0.39 a year earlier